Choi, Yun-Beom http://orcid.org/0000-0001-9930-823X
Dunn-Meynell, Ambrose A.
Marchese, Michelle
Blumberg, Benjamin M.
Gaindh, Deeya
Dowling, Peter C.
Lu, Wei
Funding for this research was provided by:
VA office of Research and Development (I01 RX001305-01A2)
National Institute of Neurological Disorders and Stroke (X01 NS073526-01A1)
Article History
Received: 8 June 2020
Accepted: 29 December 2020
First Online: 27 January 2021
Ethics approval and consent to participate
: All the mouse studies were conducted in accordance with the Animal Component of Research Protocol approved by IACUC at the VA New Jersey Health Care System, East Orange, NJ.
: All authors have consented for publication.
: PCD: US Patent Title: Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders. Application serial number: 12/792.336. Priority date: 1/23/2013, Filling date: 3/11/2013, Assignors: Peter Dowling. All other authors declare that they have no competing interests.